BTG Acquires Novel Opioid Agonist for Post-Operative Pain Control from CLL Pharma

BTG Acquires Novel Opioid Agonist for Post-Operative Pain Control from CLL Pharma

BTG Acquires Novel Opioid Agonist for Post-Operative Pain Control from CLL Pharma

London, UK 20 February 2007: BTG plc (LSE: BGC), the medical innovations company, today announces that it has acquired an opioid agonist for the control of post-operative pain from CLL Pharma, the drug development company based in Nice, France, in return for undisclosed milestone and royalty payments.

The compound, to be called BTG6001, is an orally active opioid agonist with a long duration of action, potentially reducing the amount of analgesic required for effective pain control. Owing to its unique receptor profile, BTG6001 is also expected to show a superior side effect profile compared with current opiate analgesics. BTG plans to complete preclinical development and initiate Phase I clinical studies during 2008.

Louise Makin, BTG’s Chief Executive Officer, said “We believe BTG6001 has significant advantages over current opiates and we plan to develop it for post-operative pain control and potentially other pain indications. This acquisition is in line with our objective of building a strong development pipeline in selected therapy areas, including neuroscience and oncology.”

CLL Pharma’s Chief Executive, Claude Laruelle, commented: “CLL Pharma is seeking to realise the value of its portfolio of products in pain and oncology. We are delighted to have reached this agreement with BTG and are seeking partners for other programmes. We believe BTG is an excellent partner for this programme.”

For further information contact

BTG

Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; mobile: +44 (0)7990 530605

Christine Soden, Chief Financial Officer
+44 (0)20 7575 1591

Financial Dynamics

Ben Atwell/Anna Keeble
+44 (0)20 7831 3113

About BTG

BTG in-licenses, develops and commercialises pharmaceuticals and other medical technologies. With a substantial and growing revenue stream of royalties and milestone payments from out-licensed products, BTG continues to strengthen its pipeline of preclinical and clinical development programmes. Active in the fields of oncology, diseases of ageing, neuroscience, drug repositioning and medical devices, BTG works from its offices in London, Philadelphia and Osaka with a global partner network of healthcare companies and research organisations. For further information, visit: www.btgplc.com.

Back to press releases